A First-in-Class Small-Molecule Inhibitor Targeting AVIL Exhibits Safety and Antitumor Efficacy in Preclinical Models of Glioblastoma

Investigators further examined advillin (AVIL) expression in glioblastomas (GBMs) and found that it was enriched across molecular subtypes and states, including GBM stem cells and temozolomide-resistant samples.